Medical Advocates
Saquinavir (Fortovase/Invirase)
 
Journal Citations; Adolescent/Adult
Treatment Strategies

ARV Combination Studies
 Soft-Gel Capsule Studies
Monotherapy
Salvage Therapy
 Therapeutic Strategies





 
Saquinavir Journal Main Page Main New/Newsworthy  Home Page
Last Update:  October 10, 2016
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 Perinatal data are integrated with Perinatal Conference Data in the Perinatal Data Page
 Pediatric data are integrated with Pediatric Conference Data in the Pediatric Data Page		  
ARV Combination Studies
       
 
The Rainbow Cohort: 96 Week Follow-up of Saquinavir-containing Regimens in Previously
Antiretroviral Therapy (ART)-naive and Pre-treated but Protease Inhibitor (PI)-naive HIV-infected Patients.
Knechten H, Stephan C, Mosthaf FA, et al
Eur J Med Res. 2011 Mar 28;16(3):93-100
 Abstract 

Saquinavir/Ritonavir Monotherapy as a New Nucleoside-Sparing Maintenance
Strategy in Long-Term Virologically Suppressed HIV-Infected Patients.
Bermúdez PE, Domingo P, Gutierrez M,  et al
Curr HIV Res. 2010 Jul 19
 Abstract 

Safety and Efficacy of a Saquinavir-Containing Antiretroviral Regimen in Previously
ART-Naïve or Pretreated but Protease Inhibitor-Naïve HIV-Positive Patients.
Knechten H, Stephan C, Mosthaf FA, et al 
lInfection. 2010 Mar 2
 Abstract 

FULL-TEXT PDF ARTICLE
 Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg)
together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre
prospective study.
 Lopez-Cortes LF, Viciana P, Ruiz-Valderas R, et al
AIDS Res Ther. 2010 Mar 17;7(1):5.
Paper

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together
with a fixed-dose combination of abacavir/lamivudine (600/200 mg) or tenofovir/emtricitabine
(245/300 mg) in HIV-1-infected patients.
 Bickel M, Bodtländer A, Knecht GK, et al
 J Antimicrob Chemother. 2009 Sep 22
 Abstract 

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with
saquinavir and lopinavir in extensively pre-treated patients.
 von Hentig N, Babacon E, Staszewski, et al 
Antivir Ther. 2007;12(8):1237-46.
 Abstract
 
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir
(1200/100 mg) in naive or limited PI-experienced HIV-infected patients.
 Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, et al
Antimicrob Agents Chemother. 2007 Mar 19;
 Abstract 
 
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics
of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
 Ford J, Boffito M, Maitland D, et al
 J Antimicrob Chemother. 2006 Sep 19;
 Abstract
 
 

Once-Daily Regimen of Saquinavir, Ritonavir, Didanosine, and Lamivudine in HIV-Infected
Patients With Standard Tuberculosis Therapy (TBQD Study).
 Ribera E, Azuaje C, Lopez RM, et al 
Acquir Immune Defic Syndr. 2005 Nov 1;40(3):317-323.
 Abstract
 
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered
with tenofovir diproxil fumarate in HIV-1-infected subjects.
 Boffito M, Back D, Stainsby-Tron M, et al
Br J Clin Pharmacol. 2005 Jan;59(1):38-42.
 Abstract
 
Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules
boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.
 Pai MP, Schriever CA, Diaz-Linares M, et al
Pharmacotherapy. 2004 May;24(5):592-9
 Abstract
 
Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals.
 Soria A, Gianotti N, Cernuschi M, Lazzarin A.  
New Microbiol. 2004 Jan;27(1):11-5.
 Abstract

A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug Regimen,
 in Advanced Human Immunodeficiency Virus Disease.
 Fischl MA, Ribaudo HJ, Collier AC, et al 
J Infect Dis. 2003 Sep 1;188(5):625-34.
Abstract

Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive
HIV-infected patients: the Swiss HIV Cohort Study.
Bucher HC, Bichsel M, Taffe P, et al.  
 HIV Med 2002 Oct;3(4):247-53
 Abstract
 
Comparison of initial combination antiretroviral therapy with a single protease inhibitor,
ritonavir and saquinavir,or efavirenz.
 Lucas GM, Chaisson RE, Moore RD.
AIDS 2001 Sep 7;15(13):1679-1686
Abstract
 
MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and
safety of saquinavir with stavudine and zalcitabine.
 Katlama C, Pellegrin JL, Lacoste , et al
 HIV Med 2001 Jan;2(1):20-6
Abstract
 

 
Soft-Gel Capsule Studies
       
  Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as
part of triple combination therapy for HIV-1 infection.
 Wheat LJ, Farthing C, Cohen C, et al.
Antivir Ther 2002 Sep;7(3):199-209
 Abstract

 Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine +optional lamivudine in
pregnancy and prevention of vertical HIV transmission.
 Vithayasai V, Moyle GJ, Supajatura V, et al.
Acquir Immune Defic Syndr 2002 Aug 1;30(4):410-2
 Abstract

 Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft
gelatin capsules) administration.
Buss N, Snell P, Bock J, et al;
 Br J Clin Pharmacol 2001 Sep;52(3):255-64
 Abstract
 
FULL-TEXT PDF ARTICLE
A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC
and stavudine in treatment-experienced HIV-1-infected patients..
 Smith D, Hales G, Roth N, et al.
 HIV Clin Trials 2001 Mar-Apr;2(2):97-107
 PDF Paper
 
FULL-TEXT ARTICLE
Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus
minidose ritonavir in human immunodeficiency virus-negative adults.
Kilby JM, Sfakianos G, Gizzi N, et al.
Antimicrob Agents Chemother 2000 Oct;44(10):2672-2678
 Paper
Monotherapy
       
  Short-course induction with boosted saquinavir monotherapy for naive patients with late-
stage infection.
 AIDS. 2005 Jan 28;19(2):211-2.
 Abstract
 
Salvage Therapy
       
  FULL-TEXT PDF ARTICLE
 Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly
protease inhibitor-experienced HIV-infected patients.
 Chavanet P, Piroth L, Grappin M, et al.
 HIV Clin Trials 2001 Sep-Oct;2(5):408-12
 Paper
Therapeutic Strategies
       
 
Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.
Stephan C, Bartha V, Herrmann E, , et al
 Med Microbiol Immunol. 2012 Sep 15.
 Abstract

Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study.
Coppo R, Camilla R, Porcellini MG, et al
 Nephrol Dial Transplant. 2012 Mar 19.
 Abstract

FULL-TEXT PDF ARTICLE
Marked increase in etravirine and saquinavir plasma concentrations
during atovaquone/proguanil prophylaxis
 Tommasi C, Bellagamba R, Tempestilli M, et al
Malar J. 2011 May 21;10(1):141.
 Paper

Safety and Efficacy after Switch to a Saquinavir-containing Antiretroviral Regimen in Protease
Inhibitor Pretreated HIV-positive Patients.
Stephan C, Jaeger H, Carganico A, et al
Eur J Med Res. 2010 Sep 24;15(9):369-76.
 Abstract
Saquinavir Journal Main Page Main New/Newsworthy  Home Page

Saquinavir Journal Citations